F-star Therapeutics, Inc.
F-star Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody-based cancer immunotherapies, anchored by its proprietary mAb² platform using Fcab binding domains. It was acquired by Sino Biopharm in 2023 and now operates within invoX Pharma.
- Company typePrivate
- Founded-
- Headquarters北京
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What F-star Therapeutics, Inc. does
F-star Therapeutics, Inc. was a clinical-stage biopharmaceutical company that developed bispecific antibody-based immunotherapies for the treatment of cancer. The company's core technology was its proprietary mAb² bispecific antibody platform, which uses Fcab binding domains to generate tetravalent bispecific antibodies in native human antibody formats; the platform was described as offering manufacturing simplicity, safety, and biological efficacy advantages. F-star's lead clinical asset was FS222, a CD137/PD-L1 bispecific antibody, for which positive Phase I data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting after the company's integration into Sino Biopharm.
The company was previously publicly listed on NASDAQ under the ticker FSTX. In 2023, Sino Biopharm (中国生物制药有限公司, HKEX: 1177) completed the acquisition of F-star Therapeutics, integrating its bispecific antibody platform and pipeline into the group's overseas innovation subsidiary, invoX Pharma Limited (UK). Post-acquisition, F-star ceased to operate as an independent publicly traded entity. Within the Sino Biopharm group, the F-star platform contributes to the group's antibody-based oncology pipeline development alongside complementary modalities including monoclonal antibodies, antibody-drug conjugates (ADCs), siRNA, and PROTAC. As a wholly-owned subsidiary rather than a standalone commercial enterprise, F-star generates no standalone revenue and its value is realized through the parent group's broader licensing, partnership, and commercialization activities.
F-star Therapeutics, Inc. firmographics
Firmographics- Name
- F-star Therapeutics, Inc.
- Legal name
- F-star Therapeutics, Inc.
- Website
- https://sbpgroup.com
- Company type
- Private
- Operating status
- Acquired
- Short description
- F-star Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody-based cancer immunotherapies, anchored by its proprietary mAb² platform using Fcab binding domains. It was acquired by Sino Biopharm in 2023 and now operates within invoX Pharma.
- Ownership category
- akta.pro rank
F-star Therapeutics, Inc. industry classification
Industry- Product category
- Bispecific Antibody Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where F-star Therapeutics, Inc. is headquartered
LocationHeadquarters
- HQ city
- 北京
Offices7 records
Markets served
F-star Therapeutics, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- 创新药销售: 聚焦肿瘤、肝病/心血管代谢、呼吸/自免、外科/镇痛四大核心治疗领域，通过自主研发产品及战略合作引进产品进行商业化销售。2025年全年创新产品收入达152.2亿元，年复合增长率超24%，同比增速达到26.2%
- 对外授权与合作: 将自主研发产品海外权益授权给跨国药企，获得首付款、里程碑付款及特许权使用费。如与阿斯利康就TQC3721达成最高19亿美元授权，与赛诺菲就罗伐昔替尼达成独家授权
- 产品引进与合作商业化: 通过与GSK、勃林格殷格翰、盐野义等跨国药企的战略合作，引进创新产品在中国市场商业化，如全再乐、欧乐欣、纳地美定等
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | 处方药及创新药产品组合 |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels4 records
F-star Therapeutics, Inc. product offering
Product offeringCore offering
F-star Therapeutics developed proprietary mAb² bispecific antibody technology platforms for cancer immunotherapy. Its lead clinical asset was FS222 (CD137/PD-L1 bispecific antibody), with Phase I clinical data presented at the 2024 ASCO Annual Meeting. In 2023, F-star was acquired by Sino Biopharm (中国生物制药, 1177.HK) and its technology platform was integrated into the group's UK-based overseas innovation subsidiary invoX Pharma.
Product overview
Based on the source data provided, F-star Therapeutics, Inc. appears as an acquired biotech company rather than as a primary data source. The content indicates that Sino Biopharm (中国生物制药, 1177.HK) acquired F-star in 2023 to obtain its bispecific antibody platform technology. The company's FS222 (CD137/PD-L1 bispecific antibody) was mentioned as the first research result from the F-star platform presented at an international conference following the acquisition. No other specific F-star product details, integrations, APIs, or technical specifications were found in the provided source material.
Differentiator
Problem solved
Functional benefit
Brands
- mAb²® Bispecific Antibody Technology Platform: F-star's proprietary bispecific antibody technology platform used to generate tetravalent bispecific antibodies with native human antibody formats. This platform underpinned F-star's clinical pipeline including FS222.
Products and services
- mAb² Bispecific Antibody Technology Platform F-star's proprietary bispecific antibody technology platform used to generate tetravalent bispecific antibodies with native human antibody formats. The platform uses Fcab binding domains and offers simple manufacturing processes, safety, and notable bioequivalence profiles. It underpinned F-star's clinical pipeline including FS222 and was the central asset acquired by Sino Biopharm in 2023.
- FS222 (CD137/PD-L1 bispecific antibody) F-star's lead clinical-stage bispecific antibody candidate targeting CD137 and PD-L1 for cancer immunotherapy. FS222 showed positive Phase I clinical data presented at the 2024 ASCO Annual Meeting under Sino Biopharm's ownership following the 2023 acquisition.
Quantifiable outcome
- 2025年全年创新产品收入达152.2亿元，年复合增长率超24%
- +3 more outcomes
Companies that use F-star Therapeutics, Inc.
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles1 record
F-star Therapeutics, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
F-star Therapeutics, Inc. partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered 重要, 核心 and 一般.
- Tempo Scan Pacific重要在印度尼西亚成立合资公司PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI)，中国生物制药持股51%，Tempo Scan持股49%。结合双方在创新药物研发与本地化商业化方面的优势
- 葛兰素史克(GSK)核心2026年5月，中国生物制药与GSK就Bepirovirsen乙肝治疗药物达成独家战略合作。2026年7月，进一步扩大合作，将全再乐（氟替美维吸入粉雾剂）和欧乐欣（乌美溴铵维兰特罗吸入粉雾剂）在中国内地的商业化运营权授予正大天晴，覆盖超过9000家医院及基层医疗机构
- 阿斯利康核心就自主研发的PDE3/4抑制剂TQC3721订立独家授权协议，授予阿斯利康中国以外地区开发、生产及商业化的独家许可。获得2亿美元首付款及最高19亿美元里程碑付款
- 南京大学重要正大天晴与南京大学签署战略合作协议，从科技创新、成果转化、平台共建、人才培养、产业合作五大维度全面落地，深化全方位校企合作
- 盐野义重要纳地美定（Naldemedine）（欣璞落）获NMPA批准上市，该药为全球首个获批的口服选择性外周μ-阿片受体拮抗剂，由盐野义研发，正大天晴负责中国市场商业化
- 赛诺菲核心就罗伐昔替尼达成独家全球许可协议，创下移植领域单笔交易额新记录，标志着公司从药物立项到生产质控的全链条研发能力获得国际认可
- 赫吉亚生物医药核心以12亿元人民币全资收购杭州赫吉亚生物医药，获得siRNA技术平台，在减重代谢、心脑血管及神经系统等大慢病领域布局创新管线
- 香港中文大学医学院重要正大天晴与香港中文大学医学院签署合作框架协议，推动包括临床试验、人才联合培养等在内的多领域合作，加速两地创新生物医药研究成果转化
- 华润医药商业重要正大天晴与华润医药商业在天津签署战略合作协议，在医药研发、生产、销售、流通等领域展开深度合作
- 益方生物重要2023年8月正大天晴与益方生物签订许可与合作协议，获得KRAS G12C靶向药物D-1553产品在中国大陆地区开发、注册、生产和商业化的独家许可权
- 勃林格殷格翰重要签署战略合作协议，将依托各自优势和资源，共同研发并在中国内地商业化勃林格殷格翰的肿瘤药物管线
- 礼新医药核心2025年7月全资收购礼新医药，获得全球领先的抗体发现与ADC技术平台，以及LM-302（CLDN18.2 ADC）、LM-108（CCR8单抗）等多款全球潜在FIC/BIC产品
- pHion Therapeutics一般invoX完成对下一代mRNA疫苗公司pHion Therapeutics的第二笔投资，支持其专有的RALA平台发展，推进HPV相关癌症治疗性疫苗PTX_V1进入临床试验
Scale indicators11 records
Recent moves4 records
Expansion highlights4 records
F-star Therapeutics, Inc. competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: AstraZeneca is a multinational biopharmaceutical company actively developing bispecific antibodies (e.g., Tagrisso combination strategies) and is a current partner/licensee of Sino Biopharm. It is relevant as both a broad incumbent in the bispecific space and as a counterparty providing F-star's parent validation.
- Regeneron Pharmaceuticals: Regeneron is a major biopharmaceutical company with significant bispecific antibody capabilities through its VelociBi platform (linvoseltamab, odronextamab, etc.). It is a broader incumbent comparable to F-star in terms of bispecific antibody development but operates at substantially greater scale.
Direct peers
- Innovent Biologics: Innovent Biologics is a Chinese biopharmaceutical company developing and commercializing innovative biologics including bispecific antibodies. It is directly comparable to F-star as a China-based biologics innovator with overlapping therapeutic focus areas and similar global ambitions.
- MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing bispecific antibodies and antibody-based therapeutics using proprietary DART and TRIDENT platforms. It is directly comparable to F-star as a bispecific-platform-focused clinical-stage oncology developer.
- Zymeworks: Zymeworks develops multispecific antibody therapeutics using its Azymetric and other proprietary platforms, with oncology pipeline assets in clinical development. It is directly comparable to F-star as a multispecific/bispecific platform company targeting oncology indications.
- Genmab: Genmab is a leading bispecific antibody platform company (DuoBody, HexaBody, DuoHexaBody) developing and commercializing multispecific therapeutics across oncology and immunology. It is the most directly comparable peer to F-star because it shares the bispecific platform business model and targets similar therapeutic areas.
- Merus N.V. Merus develops bispecific antibody therapeutics (Biclonics and Triclonics platforms) with multiple clinical-stage oncology candidates including petosemamab. It is directly comparable to F-star given its similar bispecific platform orientation and clinical-stage oncology focus.
- Akeso Inc. Akeso is a Chinese clinical-stage biopharmaceutical company specializing in bispecific and multispecific antibody development, including approved assets such as cadonilimab (PD-1/CTLA-4 bispecific). It is a direct peer to F-star given its bispecific-focused business model and comparable geographic base.
- Harpoon Therapeutics (acquired by Merck): Harpoon Therapeutics developed T cell-engaging bispecific antibodies using its TriTAC and ProTriTAC platforms and was acquired by Merck in 2024. It is a directly comparable bispecific platform peer, particularly relevant given its acquisition by a major pharma validating the bispecific platform thesis.
Emerging players
- Inhibrx (acquired by Sanofi): Inhibrx developed multispecific biologics including a tetravalent PD-L1/4-1BB therapeutic that was licensed by Sanofi in 2024. Its tetravalent PD-L1/CD137 bispecific is conceptually similar to F-star's FS222 (also PD-L1/CD137), making it a strong emerging-player comparison.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
F-star Therapeutics, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
F-star Therapeutics, Inc. leadership team
Management profileNumber of profiles
F-star Therapeutics, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
F-star Therapeutics, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about F-star Therapeutics, Inc.
What does F-star Therapeutics, Inc. do?
F-star Therapeutics developed proprietary mAb² bispecific antibody technology platforms for cancer immunotherapy. Its lead clinical asset was FS222 (CD137/PD-L1 bispecific antibody), with Phase I clinical data presented at the 2024 ASCO Annual Meeting. In 2023, F-star was acquired by Sino Biopharm (中国生物制药, 1177.HK) and its technology platform was integrated into the group's UK-based overseas innovation subsidiary invoX Pharma.
Is F-star Therapeutics, Inc. a public or private company?
F-star Therapeutics, Inc. is a private company. It is classified as corporate owned and is currently acquired.
When was F-star Therapeutics, Inc. founded?
F-star Therapeutics, Inc. was founded in -1.
Where is F-star Therapeutics, Inc. based?
F-star Therapeutics, Inc. is headquartered in 北京.
How does F-star Therapeutics, Inc. make money?
Three revenue lines are on record. 创新药销售 is the primary driver. The others are 对外授权与合作 and 产品引进与合作商业化.
Who are F-star Therapeutics, Inc.'s main competitors?
Broad incumbents on record are AstraZeneca and Regeneron Pharmaceuticals. Direct peers are Innovent Biologics, MacroGenics, Zymeworks, Genmab, Merus N.V., Akeso Inc. and Harpoon Therapeutics (acquired by Merck). Inhibrx (acquired by Sanofi) is listed as an emerging player.
Does F-star Therapeutics, Inc. have an API?
No public API is recorded for F-star Therapeutics, Inc..
What industry is F-star Therapeutics, Inc. in?
F-star Therapeutics, Inc.'s product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.